Abstract:Aims: Presentation of acute events in patients with atherosclerosis remains unpredictable even after controlling for classical risk factors. MicroRNAs (miRNAs) measured in liquid biopsies could be good candidate biomarkers to improve risk prediction. Here, we hypothesized that miRNAs could predict atherosclerotic plaque progression and clinical event presentation in familial hypercholesterolaemia (FH) patients. Methods and results: Circulating miRNAs (plasma, exosomes, and microvesicles) were investigated by TaqMan Array and RT-qPCR assays. Patients with genetic diagnosis of FH and healthy relatives from the SAFEHEART cohort were included. A differential signature of 10 miRNA was obtained by comparing two extreme phenotypes consisting of FH patients suffering a cardiovascular event (CVE) within a 8-year follow-up period (FH-CVE, N = 42) and non-FH hypercholesterolaemic relatives from the same cohort, matched for age and treatment, without CVE during the same period (nFH-nCVE, N = 30). The validation studies included two independent groups of patients with FH background (discovery group, N = 89, validation group N = 196), developing a future CVE (FH-CVE) or not (FH-nCVE) within the same time period of follow-up. Of the 10 miRNAs initially selected, miR-133a was significantly higher in FH-CVE than in FH-nCVE patients. Receiver operating characteristic analysis confirmed miR-133a as the best microRNA for predicting CVE in FH patients (0.76 ± 0.054; P < 0.001). Furthermore, Kaplan-Meier and COX analysis showed that high plasma miR-133a levels associated to the higher risk of presenting a CVE within the next 8 years (hazard ratio 3.89, 95% confidence interval 1.88-8.07; P < 0.001). In silico analysis of curate biological interactions related miR-133a with target genes involved in regulation of the cell-membrane lipid-receptor LRP6 and inflammatory cytokines (CXCL8, IL6, and TNF). These predictions were experimentally proven in human macrophages and endothelial cells transfected with agomiR-133a. Conclusion: Elevated levels of miR-133a in the circulation anticipate those FH patients that are going to present a clinical CVE within the next 2 years (average). Mechanistically, miR-133a is directly related with lipid- and inflammatory signalling in key cells for atherosclerosis progression.

PROGNOSTIC VALUE OF MICRORNA-126-3P FOR CARDIOVASCULAR EVENTS IN A GENERAL POPULATION

Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease

Circulating miRNA 122-5p Expression Predicts Mortality and Cardiovascular Events in Chronic Hemodialysis Patients: A Multicentric, Pilot, Prospective Study

Circulating microRNAs as biomarkers of chronic kidney disease and its association with renal and cardiovascular outcomes in non-dialysis patients

Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention.

High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism - The HUNT study

Selected miRNAs in urinary extracellular vesicles show promise for non-invasive diagnostics of diabetic kidney disease

Abstract P124: Human Small Artery MicroRNA Expression Profiles: Changes in Type 2 Diabetes and Associations with Endothelial Function

Urinary Mirna-29A-3p Levels Are Associated with Metabolic Parameters Via Regulation of IGF1 in Patients with Metabolic Syndrome.

MiRNA Expression is Associated with Clinical Variables Related to Vascular Remodeling in the Kidney and the Brain in Type 2 Diabetes Mellitus Patients

Expression of microRNA Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease

MicroRNAs in Peripheral Mononuclear Cells as Potential Biomarkers in Hypertensive Patients With Heart Failure With Preserved Ejection Fraction

Preanalytical considerations in quantifying circulating miRNAs that predict end-stage kidney disease in diabetes

High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients

miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy

Differential Role of Circulating microRNAs to Track Progression and Pre-Symptomatic Stage of Chronic Heart Failure: A Pilot Study

INVESTIGATION OF MICRORNA LEVELS IN BLOOD PLASMA IN PREGNANT WOMEN WITH GESTATIONAL ARTERIAL HYPERTENSION, PREECLAMPSIA, AND FETAL GROWTH RETARDATION SYNDROME

Plasma Microrna-186 and Proteinuria in Focal Segmental Glomerulosclerosis.

The Investigation of the Plasma Mir-126 and Mir-143 Expression in Patients with Coronary Heart Disease

Plasma Mir-142 Predicts Major Adverse Cardiovascular Events As an Intermediate Biomarker of Dual Antiplatelet Therapy

Identification of circulating microRNA-126-3p as a new biomarker for coronary artery calcification